Real-world first-line serplulimab-based immunochemotherapy for extensive-stage small cell lung cancer: The Multicenter ASTRUM-005R study
ASCO 2024
Neoadjuvant chemoimmunotherapy in patients with limited-stage small cell lung cancer: A retrospective study
ASCO 2024
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial
ASCO 2024
Neoadjuvant serplulimab in combination with concurrent chemoradiotherapy for locally advanced, resectable esophagogastric junction adenocarcinoma
ASCO 2024
Effectiveness and safety analysis of serplulimab-based regimens in patients withHER2-negative advanced gastric cancer from a real-world retrospective study
